

Jenpharm Life Sciences Address

at december 31, 2013, achillion had cash, cash equivalents, marketable securities and interest receivable of approximately 159.1 million

jenpharm life sciences

of the developments that underpin today's biotechnology and genetic engineering came about in the first

jenpharm life sciences address